ERYTECH reports additional positive Phase III results from clinical study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia Post author:admERY Post published:December 8, 2014 Post category:Newsroom ERYTECH reports additional positive Phase III results from the pivotal study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia. You Might Also Like ERYTECH to Present at Morgan Stanley Global Healthcare Conference September 12, 2017 ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer November 25, 2019 ERYTECH gives feedback on its first Investor R&D Day and provides a financial and business update for Q4 2013 January 27, 2014
ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer November 25, 2019
ERYTECH gives feedback on its first Investor R&D Day and provides a financial and business update for Q4 2013 January 27, 2014